Triple Negative Breast Cancer News and Research

RSS

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

24 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

13 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

11 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Women who have estrogen (ER) negative breast cancer may have more drug treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene.

11 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

Study finds BRACAnalysis vital for triple negative breast cancer patients

Myriad Genetics, Inc. announced today that results from a preliminary study indicate that BRCA germline mutations occur at a high frequency in women with triple negative breast cancer, sufficiently high enough to justify screening of all women with TNBC.

5 Oct 2010

Vigorous exercise reduces breast cancer risk: Study

Vigorous exercise of more than two hours per week reduces the risk of developing breast cancer in postmenopausal African-American women by 64 percent, compared to women of the same race who do not exercise, according to researchers at Georgetown Lombardi Comprehensive Cancer Center.

4 Oct 2010

Vitamin D deficiency in African-American women can increase risk of aggressive breast cancer: Study

African-American women had lower vitamin D levels than white women, and vitamin D deficiency was associated with a greater likelihood for aggressive breast cancer, according to data presented at the Third AACR Conference on the Science of Cancer Health Disparities.

3 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2010

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

Patients with triple negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

BRCA1 gene mutation increases breast cancer risk: Research

Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, discoveries from an international research team led by Mayo Clinic researchers show that some of those persons may possess additional genetic variants that modify their risk. These new findings enhancing individualized medicine appear in the current Nature Genetics.

20 Sep 2010

African ancestry associated with triple-negative breast cancer: Study

A new study finds that African ancestry is linked to triple-negative breast cancer, a more aggressive type of cancer that has fewer treatment options.Researchers at the University of Michigan Comprehensive Cancer Center found that, among women with breast cancer, 82 percent of African women were triple negative, 26 percent of African-Americans were and 16 percent of white Americans were.

23 Jul 2010

Researchers to receive $1.2M from Susan G. Komen for the Cure for breast cancer research

Four researchers from Detroit, Michigan's Barbara Ann Karmanos Cancer Institute and Wayne State University will receive a total of $1.2 million from Susan G. Komen for the Cure to help advance research to better detect, prevent and eliminate breast cancer. The $1.2 million awarded to these outstanding scientists is part of the $59 million portfolio of research grants that Susan G. Komen for the Cure has awarded this year alone to scientists across the globe to help accelerate innovative breast cancer research.

17 Jul 2010

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat an aggressive type of breast cancer prevalent in young women, particularly young African-American women.

16 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Triple Negative Breast Cancer News and Research

A new treatment landscape for triple-negative breast cancer

Study: EGFR inhibtion may help treat triple negative breast cancer

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Merck Serono to present Erbitux data at ESMO Congress

Study finds BRACAnalysis vital for triple negative breast cancer patients

Vigorous exercise reduces breast cancer risk: Study

Vitamin D deficiency in African-American women can increase risk of aggressive breast cancer: Study

Breast cancer breakthrough

Triple negative breast cancer patients with BRCA gene mutations have low risk of recurrence: Research

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

BRCA1 gene mutation increases breast cancer risk: Research

African ancestry associated with triple-negative breast cancer: Study

Researchers to receive $1.2M from Susan G. Komen for the Cure for breast cancer research

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News